NRG1 Fusion clinical trials at UC Cancer

• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

  open to eligible people ages 18 years and up

  This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.

  at UC Irvine

• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

  open to eligible people ages 18 years and up

  Open-label, Phase 2, single treatment arm, 3 cohorts

  at UC Irvine

Last updated: May 21, 2020